Ocugen Inc. is tackling retinitis pigmentosa (RP), which is caused by mutations in well over 100 mutations.
Chester County biopharmaceutical company Ocugen has finalized an agreement with Bharat Biotech of India to co-develop Bharat’s Covid-19 vaccine for the United States market.
While Ocugen has focused on developing gene therapy treatments for retinal diseases since its inception in 2013, the Malvern biopharmaceutical company expanded into a new arena two weeks ago. On Dec. 22, Ocugen announced it signed a binding letter of intent with Bharat Biotech of India to co-develop Bharat’s Covid-19 vaccine candidate for the United States market.
The Indian company Bharat Biotech partnered with the National Institute of Virology and the Indian Council of Medical Research to develop an inactivated coronavirus vaccine called Covaxin.
India’s drugs regulator on Saturday recommended for emergency use a locally developed coronavirus vaccine called COVAXIN, which is expected to be a backup to the AstraZeneca/Oxford shot. COVAXIN has been developed by Bharat Biotech, a company based in Hyderabad, with backing from the state-run Indian Council of Medical Research (ICMR).
CEOs of biopharma organizations face unprecedented challenges as they lead their companies amid a global pandemic, shoring up their organizations during turmoil, and learning valuable lessons along the way.